SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Valuation and Earnings
This table compares SOPHiA GENETICS and Pulmonx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $65.17 million | 5.36 | -$62.49 million | ($0.46) | -11.24 |
| Pulmonx | $83.79 million | 0.85 | -$56.39 million | ($1.41) | -1.22 |
Risk & Volatility
SOPHiA GENETICS has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Profitability
This table compares SOPHiA GENETICS and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -41.13% | -37.75% | -18.75% |
| Pulmonx | -61.91% | -77.58% | -37.90% |
Analyst Ratings
This is a summary of current ratings and target prices for SOPHiA GENETICS and Pulmonx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 0 | 2 | 0 | 2.33 |
| Pulmonx | 1 | 4 | 5 | 0 | 2.40 |
SOPHiA GENETICS presently has a consensus price target of $7.00, indicating a potential upside of 35.40%. Pulmonx has a consensus price target of $6.81, indicating a potential upside of 295.76%. Given Pulmonx’s stronger consensus rating and higher probable upside, analysts plainly believe Pulmonx is more favorable than SOPHiA GENETICS.
Institutional and Insider Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Pulmonx beats SOPHiA GENETICS on 8 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
